Literature DB >> 30679179

IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis.

Kumar S Bishnupuri1, David M Alvarado2, Alexander N Khouri2, Mark Shabsovich2, Baosheng Chen2, Brian K Dieckgraefe2, Matthew A Ciorba1.   

Abstract

The tryptophan-metabolizing enzyme indoleamine 2,3 dioxygenase 1 (IDO1) is frequently overexpressed in epithelial-derived malignancies, where it plays a recognized role in promoting tumor immune tolerance. We previously demonstrated that the IDO1-kynurenine pathway (KP) also directly supports colorectal cancer growth by promoting activation of β-catenin and driving neoplastic growth in mice lacking intact adaptive immunity. In this study, we sought to delineate the specific role of epithelial IDO1 in colon tumorigenesis and define how IDO1 and KP metabolites interact with pivotal neoplastic signaling pathways of the colon epithelium. We generated a novel intestinal epithelial-specific IDO1 knockout mouse and utilized established colorectal cancer cell lines containing β-catenin-stabilizing mutations, human colorectal cancer samples, and human-derived epithelial organoids (colonoids and tumoroids). Mice with intestinal epithelial-specific knockout of IDO1 developed fewer and smaller tumors than wild-type littermates in a model of inflammation-driven colon tumorigenesis. Moreover, their tumors exhibited reduced nuclear β-catenin and neoplastic proliferation but increased apoptosis. Mechanistically, KP metabolites (except kynurenic acid) rapidly activated PI3K-Akt signaling in the neoplastic epithelium to promote nuclear translocation of β-catenin, cellular proliferation, and resistance to apoptosis. Together, these data define a novel cell-autonomous function and mechanism by which IDO1 activity promotes colorectal cancer progression. These findings may have implications for the rational design of new clinical trials that exploit a synergy of IDO1 inhibitors with conventional cancer therapies for which Akt activation provides resistance such as radiation.Significance: This study identifies a new mechanistic link between IDO1 activity and PI3K/AKT signaling, both of which are important pathways involved in cancer growth and resistance to cancer therapy. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30679179      PMCID: PMC6420842          DOI: 10.1158/0008-5472.CAN-18-0668

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells.

Authors:  Katarzyna Walczak; Wojciech Dąbrowski; Ewa Langner; Wojciech Zgrajka; Jacek Piłat; Tomasz Kocki; Wojciech Rzeski; Waldemar A Turski
Journal:  Scand J Gastroenterol       Date:  2011-05-26       Impact factor: 2.423

2.  Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

Authors:  Sara M Johnson; Pat Gulhati; Bill A Rampy; Yimei Han; Piotr G Rychahou; Hung Q Doan; Heidi L Weiss; B Mark Evers
Journal:  J Am Coll Surg       Date:  2010-05       Impact factor: 6.113

3.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Authors:  De-Yan Hou; Alexander J Muller; Madhav D Sharma; James DuHadaway; Tinku Banerjee; Maribeth Johnson; Andrew L Mellor; George C Prendergast; David H Munn
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

4.  Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Authors:  Holly K Koblish; Michael J Hansbury; Kevin J Bowman; Gengjie Yang; Claire L Neilan; Patrick J Haley; Timothy C Burn; Paul Waeltz; Richard B Sparks; Eddy W Yue; Andrew P Combs; Peggy A Scherle; Kris Vaddi; Jordan S Fridman
Journal:  Mol Cancer Ther       Date:  2010-02-02       Impact factor: 6.261

5.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Authors:  Rikke B Holmgaard; Dmitriy Zamarin; Yanyun Li; Billel Gasmi; David H Munn; James P Allison; Taha Merghoub; Jedd D Wolchok
Journal:  Cell Rep       Date:  2015-09-24       Impact factor: 9.423

Review 7.  Metabolic control of tumour progression and antitumour immunity.

Authors:  Lei Huang; Andrew L Mellor
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

Review 8.  The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy.

Authors:  Lilla Hornyák; Nikoletta Dobos; Gábor Koncz; Zsolt Karányi; Dénes Páll; Zoltán Szabó; Gábor Halmos; Lóránt Székvölgyi
Journal:  Front Immunol       Date:  2018-01-31       Impact factor: 7.561

9.  Beta-catenin cleavage enhances transcriptional activation.

Authors:  Tatiana Goretsky; Emily M Bradford; Qing Ye; Olivia F Lamping; Tomas Vanagunas; Mary Pat Moyer; Patrick C Keller; Preetika Sinh; Josep M Llovet; Tianyan Gao; Qing-Bai She; Linheng Li; Terrence A Barrett
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.996

10.  Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.

Authors:  Jair Machado Espindola-Netto; Claudia C S Chini; Mariana Tarragó; Enfeng Wang; Shamit Dutta; Krishnendu Pal; Debabrata Mukhopadhyay; Mauro Sola-Penna; Eduardo N Chini
Journal:  Oncotarget       Date:  2017-06-29
View more
  50 in total

1.  Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota.

Authors:  David M Alvarado; Baosheng Chen; Micah Iticovici; Ameet I Thaker; Nattalie Dai; Kelli L VanDussen; Nurmohammad Shaikh; Chai K Lim; Gilles J Guillemin; Phillip I Tarr; Matthew A Ciorba
Journal:  Gastroenterology       Date:  2019-07-17       Impact factor: 22.682

Review 2.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

3.  Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.

Authors:  Baosheng Chen; David M Alvarado; Micah Iticovici; Nathan S Kau; Haeseong Park; Parag J Parikh; Dinesh Thotala; Matthew A Ciorba
Journal:  Cancer Immunol Res       Date:  2020-03-03       Impact factor: 11.151

4.  Metabolic Stress and Immunity: Nutrient-Sensing Kinases and Tryptophan Metabolism.

Authors:  Johanna M Gostner; Dietmar Fuchs; Katharina Kurz
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Constructed the ceRNA network and predicted a FEZF1-AS1/miR-92b-3p/ZIC5 axis in colon cancer.

Authors:  Xiaoping Yang; Pingfan Wu; Zirui Wang; Xiaolu Su; Zhiping Wu; Xueni Ma; Fanqi Wu; Dekui Zhang
Journal:  Mol Cell Biochem       Date:  2022-10-11       Impact factor: 3.842

6.  Dynamic proteomic change of tumor and immune organs in an immune-competent hepatocellular carcinoma mouse model.

Authors:  Jiaqi Jiao; Linlin Ji; Xianju Li; Zhan Gao; Guangshun Wang; Jun Qin; Yini Wang; Yi Wang
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 7.  Immunity, immunotherapy, and rectal cancer: A clinical and translational science review.

Authors:  Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba
Journal:  Transl Res       Date:  2020-12-08       Impact factor: 7.012

Review 8.  Not Only Immune Escape-The Confusing Role of the TRP Metabolic Pathway in Carcinogenesis.

Authors:  Iwona Kwiatkowska; Justyna Magdalena Hermanowicz; Alicja Przybyszewska-Podstawka; Dariusz Pawlak
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

9.  Prognostic value of the PrPC-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype.

Authors:  Alexandre Ghazi; Delphine Le Corre; Camilla Pilati; Julien Taieb; Thomas Aparicio; Audrey Didelot; Shoukat Dedhar; Claire Mulot; Karine Le Malicot; Fatima Djouadi; Aurélien de Reynies; Jean-Marie Launay; Pierre Laurent-Puig; Sophie Mouillet-Richard
Journal:  Oncoimmunology       Date:  2021-06-28       Impact factor: 8.110

10.  Indoleamine 2,3-Dioxygenase 1 (IDO1) Promotes Cardiac Hypertrophy via a PI3K-AKT-mTOR-Dependent Mechanism.

Authors:  Yang Liu; Shuang Li; Zhanqun Gao; Shuangjia Li; Qingyun Tan; Yanmei Li; Dongwei Wang; Qingdong Wang
Journal:  Cardiovasc Toxicol       Date:  2021-05-21       Impact factor: 3.231

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.